Cosmos Health projects $6M revenue from Oliv18 supplement launch

Cosmos Health Inc., a diversified global healthcare group, is projecting revenue of over $6 million from its new Oliv18 nutraceutical supplement within the next 12 to 18 months, the company announced in a press release. Analysts anticipate the product to generate approximately $4.3 million in gross profit, with an expected gross margin of 72%.

Oliv18 is a USDA and EU organic certified whole olive polyphenol formulation produced through a solvent-free process, targeting cardiovascular health and antioxidant supplement categories. The company plans to roll out the product in stages, starting with direct-to-consumer e-commerce before expanding to selected retail channels.

The projection incorporates internal assumptions around pricing, sales volumes, repeat purchases, and distribution growth, subject to the execution of the company’s commercialization plans. Greg Siokas, CEO of Cosmos Health, stated that Oliv18 extends the company’s 18 Series into two established consumer wellness categories where demand is shifting towards products backed by scientific substantiation.

Cosmos Health owns a portfolio of pharmaceutical and nutraceutical brands, manufactures products through its subsidiary Cana Laboratories S.A., and distributes them in Greece and the UK.